ALKS vs NBIX · P/E 14, rev $1.56B vs P/E 45, rev $2.36B
Alkermes Plc (ALKS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ALKS and NBIX stock pages for the full models.
Not investment advice.